Using angiotensin converting enzyme inhibitors in African-American hypertensives: A new approach to treating hypertension and preventing target-organ damage

Current Medical Research and Opinion

Volumn 16, Issue 2, 2000, Pages 66-79

  Flack, John M ^a,d   Mensah, George A ^b   Ferrario, Carlos M ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

African Americans; Angiotensin converting enzyme inhibitors

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; RENIN;

BLOOD PRESSURE MONITORING; CAUCASIAN; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ETHNIC GROUP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE;

EID: 0033933020     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/0300799009117011     Document Type: Review

References (75)

1. Siegel, D. and Lopez, J. (1997). Trends in antihypertensive drug use in the United States. Do the JNCV recommendations affect prescribing? JAMA, 278, 1745-1748.
2. Cornoi-Huntley, J., LaCroix, A. Z. and Havlik, R. J. (1989). Race and sex differentials in the impact of hypertension in the United States. Arch. Intern. Med., 149, 780-788.
3. Flack, J. M., Neaton, J., Daniels, B. and Esunge, P. (1993). Ethnicity and renal disease: lessons from multiple risk factor intervention trial and treatment of mild hypertension study. Am. J. Kidney Dis., 21(4) (Suppl I), 31-40.
4. Roccella, E. J. and Lenfant, C. (1989). Regional and racial differences among stroke victims in the United States. Clin. Cardiol., 12, IV-18-IV-22.
5. Qualheim, R. E., Rostand, S. G., Kirk, K. A., Rutsky, E. A. and Luke, R. G. (1991). Changing patterns of end-stage renal disease due to hypertension. Am. J. Kidney Dis., 18, 336-343.
6. Flack, J. M., Ensrud, K. E., Mascioli, S. et al. (1991). Racial and ethnic modifiers of the salt-blood pressure response. Hypertension, 17 (Suppl I), I-115-I-121.
7. Faulkner, B. and Kushner, H. (1990). Effect of chronic sodium loading on cardiovascular responses in young blacks and whites. Hypertension, 15, 36-43.
8. Suzuki, H., Ferrario, C. M., Speth, R. C. et al. (1983). Alterations in plasma and cerebrospinal fluid norepinephrine and angiotensin II during the development of renal hypertension in conscious dogs. Hypertension, 5 (Suppl I), I-139-I-148.
9. Kohara, K., Brosnihan, K. B. and Ferrario, C. M. (1993). Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides, 14, 883-891.
10. Allan, D. R., McKnight, J. A., Kifor, I., Coletti, C. M. and Hollenberg, N. K. (1994). Converting enzyme inhibition and renal tissue angiotensin II in the rat. Hypertension, 24(4), 516-522.
11. Weishaar, R. E., Panck, R. L., Major, T. C., Simmerman, J., Rapundalo, S. T. and Taylor, D. G. Jr. (1991). Evidence for a functional tissue renin-angiotensin system in the rat mesenteric vasculature and its involvement in regulating blood pressure. J. Pharmacol. Expl. Ther., 256(2), 568-574.
12. Kaplan, H. R., Taylor, D. G., Olson, S. C. et al. (1989). Quinapril - a preclinical review of the pharmacology, pharmacokinetics and toxicology. Angiology, 40, 335-350.
13. Luft, F. C., Miller, J. Z., Grim, C. E. et al. (1991). Salt sensitivity and resistance of blood pressure. Hypertension, 17 (Suppl I), I-102-I-108.
14. Walker, W. G., Neaton, J. D., Cutler, J. A., Neuwirth, R. and Cohen, J. D. (1992). Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA, 268, 3085-3091.
15. Walker, W. G., Horvath, J. S., Moore, M. A., Whelton, P. and Russell, R. P. (1976). Relation between plasma renin activity, angiotensin, and aldosterone and blood pressure in mild untreated hypertension. Circ. Res., 38, 470-476.
16. Campbell, D. J., Kladis, A., Skinner, S. L. and Whitworth, J. A. (1991). Characterization of angiotensin peptides in plasma of anephric man. J. Hypertens., 9, 265-274.
17. Yamada, T., Horiuchi, M. and Dzau, V. J. (1996). Angiotensin II type 2 receptor mediates programed cell death. Proc. Natl. Acad. Sci. USA, 93(1), 156-160.
18. Kimura, G., Deguchi, F., Kojima, S. et al. (1988). Antihypertensive drugs and sodium restriction. Am. J. Hypertens., 1, 372-379.
19. Joubert, P. H. and Brandt, H. D. (1990). Apparent racial difference in response to angiotensin I infusion. Eur. J. Clin. Pharmacol., 39, 183-185.
20. Sharma, A. M, Schattenfroh S., Thiede, H. M., Oelkers, W. and Distler, A. (1992). Effects of sodium salts on pressor reactivity in salt-sensitive men. Hypertension, 19, 541-548.
21. Redgrave, J., Rabinowe, S., Hollenberg, N. K. and Williams, G. H. (1985). Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertension. J. Clin. Invest., 75, 1285-1290.
22. Stokes, J. B. III (1974). The national high blood pressure education program. J. Am. Pharm. Assoc., 14, 172-176.
23. The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC VI). Arch. Intern. Med., 157(21), 2413-2446.
24. Dannenberg, A. L., Drizd, T., Horan, M. J. et al. (1987). Progress in the battle against hypertension. Changes in blood pressure levels in the United States from 1960 to 1980. Hypertension, 10, 226.
25. Roberts, J. (1975). Blood pressure of persons 18-74 years: United States, 1971-72. Data from the National Health Survey, Washington, DC; National Center for Health Statistics, 1975. Vital and Health Statistics, Series 11, No. 150. DHEW Publication No. 75-1632.
26. Rowland, M. and Roberts, J. (1982). Blood pressure levels and hypertension in persons aged 6-74 years: United States, 1976-80. National Center for Health Statistics, Hyattsville, Md; October, 1982. Advance Data from Vital and Health Statistics, No. 84. DHHS Publication No. 82-1250.
27. Burt, V. L., Whelton, P., Roccella, E. J., et al. (1995). Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension, 25, 305-313.
28. Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B. and Castelli, W. P. (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med., 322, 1561-1566.
29. Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D. and Laragh, J. H. (1991). Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med., 114, 345-352.
30. Cooper, R. S., Simmons, B. E., Castaner, A., Santhanam, V., Ghali, J. and Mar, M. (1990). Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am. J. Cardiol., 65, 441-445.
31. Ghali, J. K., Liao, Y., Simmons, B., Castaner, A., Cao, G. and Cooper, R. S. (1992). The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann. Intern. Med., 117, 831-836.
32. Mensah, G. A, Liao, Y. and Cooper, R. S. (1995). Left ventricular hypertrophy as a risk factor in patients with or without coronary artery disease. Cardiovasc. Risk Factors, 5, 67-74.
33. Schunkert, H., Jackson, B., Tang, S. S. et al. (1993). Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation, 87, 1328-1339.
34. Kaneko, K., Susic, D., Nunez, E. and Frohlic, E. D. (1997). ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Am. J. Med. Sci., 314(1), 21-27.
35. Dahlof, B. and Hannson, L. (1992). Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorthiazide. J. Hypertension, 10, 1513-1524.
36. Papademetriou, V. (1994). Effects of diuretics on cardiac arrhythmias and left ventricular hypertrophy in hypertension. Cardiology, 84 (Suppl 2), 43-47.
37. Agabiti-Rosei, E., Muiesan, M. L., Rizzoni, D., Zulli, R. et al. (1994). Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J. Cardiovasc. Pharmacol., 24 Suppl A, S37-S43.
38. Szlacheie, J., Tuban, J. F., Vollmer, C. et al. (1989). Effect of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension. Am. J. Cardiol., 63, 198-201.
39. Glasser, S. P., Koehn, D. K. and Powell, R. (1989). Regression of left ventricular hypertrophy in treated hypertensive patients with dievanol and metoprolol - a double blind randomized study. J. Clin. Pharmacol., 29, 791-797.
40. de Divitis, O., Celentano, A., De Simone, G. et al. (1993). Management of the patient with left ventricular hypertrophy. Eur. Heart J., 14 (Suppl D), 22-32.
41. Oliveri, R. (1988). Effects of different antihypertensive drugs on left ventricular function. Drugs, 35 (Suppl 6), 83-89.
42. Cruickshank, J. M. (1992). Reversibility of left hypertrophy. Blood Pressure, 1 (Suppl 1), 32-33.
43. Dahlof, B., Pennert, K. and Hansson, L. (1992). Regression of left ventricular hypertrophy - a meta-analysis. Clin. Expl. Hyp. Part A, 14(1-2), 173-180.
44. Koren, M. J., Mensah, G. A., Blake, J., Laragh, J. H. and Devereux, R. B. (1993). Comparison of left ventricular mass and geometry in black and white patients with essential hypertension. Am. J. Hypertens., 6, 815-823.
45. Brilla, C. G., Maisch, B. and Weber, K. T. (1993). Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin. Invest., 71, S35-S41.
46. Weber, K. T. (1989). Cardiac interstitium in health and disease: the fibrillar collagen network. J. Am. Coll. Cardiol., 13, 1637-1652.
47. Lund-Johansen, P. and Omvik, P. (1993). Cardiac effects of ACE inhibition. J. Cardiovasc. Pharmacol., 22 (Suppl 1), S36-S40.
48. Federman, M., Risti, B. and Hess, O. M. (1994). Left venticular insuffiency: systolic versus diastolic dysfunction (in German). Schweizerrishe Medizinische Wochenschrift. Journal Suisse de Medecine, 124(26), 1196-1202.
49. Brilla, C. G., Scheer, C. and Rupp, H. (1997). Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J. Hypertens., 15(6) (Suppl), S13-S19.
50. Sun, Y. (1997). Local angiotensin II and myocardial fibrosis. Adv. Expl. Med. Biol., 432, 55-61.
51. Funck, R. C., Wilke, A., Rupp, H. and Brilla, C. G. (1997). Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv. Expl. Med. Biol., 432, 35-44.
52. Garg, R, Packer, M., Pitt, B. and Yusuf, S. (1993). Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J. Am. Coll. Cardiol., 22, 3A-5A.
53. Bourassa, M. G., Gurne, O., Bangdiwala, S. I. et al. (1993). Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J. Am. Coll. Cardiol., 22, 14A-19A.
54. Stafford, R. S., Saglam, D. and Blumenthal, D. (1997). National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch. Intern. Med., 157 (21), 2460-2464.
55. The CONSENSUS Trial Study Group (1987). Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med., 316, 1429-1435.
56. Struthers, A. D. (1997). Rationalizing the heart failure trials: from theory to practice. Eur. Heart J., 18 (Suppl E), E5-E8.
57. Maynard, C., Fisher, L. D., Passamani, E. R. et al. (1986). Blacks in the coronary artery surgery study: risk factors and coronary artery disease. Circulation, 74, 64.
58. Simmons, B. E., Castaner, A., Campo, A. et al. (1988). Coronary artery disease in blacks of lower socioeconomic status: angiographic findings from the Cook County Hospital Heart Disease Registry. Am. Heart J., 116, 90-97.
59. Strong, J. P., Oalmann, M. C., Newman, W. P. III et al. (1984). Coronary heart disease in young black and white males in New Orleans: Community Pathology Study. Am. Heart J., 108, 747-759.
60. Tofler, G. H., Stone, P. H., Muller, J. E. et al. (1987). Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J. Am. Coll. Cardiol., 9, 473-482.
61. Mensah, G. A., Cooper, R. S. and Liao, Y. (1994). Sex-related outcome differences after acute myocardial Infarction (corr). Ann. Intern. Med., 121, 815-816.
62. Pfeffer, M. A., Braunwald, E., Moye, L. A. et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med., 327, 669-677.
63. Blythe, W. B. and Maddux, F. W. (1991). Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980 to 1986. Am. J. Kidney Dis., 18, 33-37.
64. Relman, A. S. (1982). Race and end-stage renal disease [Editorial]. N. Engl. J. Med., 306, 1290-1291.
65. Perneger, T. V., Whelton, P. K., Klag, M. J. and Rossiter, K. A. (1995). Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am. J. Epidemiol., 141, 10-15.
66. Klag, M. J., Whelton, P. K., Randall, B. L., Neaton, J. D., Brancati, F. L. and Stamler, J. (1997). End-stage renal disease in African-American men: 16-year MRFIT findings. JAMA, 277, 1293-1298.
67. Lewis, E. J., Hunsicker, L. G., Bain, R. P. and Rohde, R. D. for the Collaborative Study Group (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med., 329, 1456-1462.
68. Giatras, I., Lau, J. and Levey, A. S. for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group (1997). Effect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann. Intern. Med., 127, 337-345.
69. Saunders, E., Weir, M. R., Kong, B. W. et al. (1990). A comparison of the efficacy and safety of a beta-blocker, a calcium blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch. Intern. Med., 150, 1707-1713.
70. Veterans Administration Cooperative Study Group on Antihypertensive Agents (1982). Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. Results of short-term titration with emphasis on racial difference in response. JAMA, 248, 1996-2003.
71. Wing, W., Ferguson, R. K. and Vlasses, P. H. (1991). Calcium antagonist in elderly and black hypertensive patients. Arch. Intern. Med., 1551, 2154-2162.
72. Drayer, J. I. M. and Weber, M. A. (1983). Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension, 5 (Suppl III), III-108-III-113.
73. Flack, J. M. Personal communication.
74. Weir, M. R., Hall, P. S., Bohrens, M. T. and Flack, J. M. (1997). Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension, 30(3, Pt 1), 422-427.
75. Mikami, H., Suzuki, H., Smeby, R. R. and Ferrario, C. M. (1985). Cerebrospinal fluid angiotensin II immunoreactivity is not derived from the plasma. Hypertension, 7, 65-71.